These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 2252662)
21. Comparison of hemodialysis and peritoneal dialysis in the management of anemia related to chronic renal disease. Korbet SM Semin Nephrol; 1989 Mar; 9(1 Suppl 1):9-15. PubMed ID: 2648520 [TBL] [Abstract][Full Text] [Related]
22. Severity of AIDS and the response to EPO in uremia. Ifudu O; Matthew JJ; Mayers JD; Macey LJ; Brezsnyak W; Reydel C; McClendon E; Surgrue T; Rao S; Friedman EA Am J Kidney Dis; 1997 Jul; 30(1):28-35. PubMed ID: 9214398 [TBL] [Abstract][Full Text] [Related]
23. A cost-effectiveness analysis of anemia screening before erythropoietin in patients with end-stage renal disease. Hutchinson FN; Jones WJ Am J Kidney Dis; 1997 May; 29(5):651-7. PubMed ID: 9159297 [TBL] [Abstract][Full Text] [Related]
24. [Recombinant human erythropoietin (rh-EPO) in chronic, dialysis-dependent renal failure: effects on macro- and microcirculation and hematologic parameters]. Köhler M; Mörsdorf S; Jung F; Braun B; Waldhausen P; Pindur G; Weber U; Bosslet R; Bambauer R; Jutzler GA Beitr Infusionsther; 1990; 26():89-95. PubMed ID: 1703909 [TBL] [Abstract][Full Text] [Related]
25. Erythropoietin response to blood loss in hemodialysis patients in blunted but preserved. Ross RP; McCrea JB; Besarab A ASAIO J; 1994; 40(3):M880-5. PubMed ID: 8555638 [TBL] [Abstract][Full Text] [Related]
26. Effect of low dose recombinant human omega erythropoietin (rHuEPO) on anaemia in patients on hemodialysis. Acharya VN; Sinha DK; Almeida AF; Pathare AV J Assoc Physicians India; 1995 Aug; 43(8):539-42. PubMed ID: 8772973 [TBL] [Abstract][Full Text] [Related]
27. Multicenter study with recombinant human erythropoietin. Tanaka H; Kan E; Takegaki Y; Inariba H; Yoshimoto M; Ohno Y; Maekawa M; Tatsumi N; Kishimoto T Artif Organs; 1993 Apr; 17(4):213-8. PubMed ID: 8498899 [TBL] [Abstract][Full Text] [Related]
28. Epoetin requirement does not depend on dialysis dose when Kt/N > 1.33 in patients on regular dialysis treatment with cellulosic membranes and adequate iron stores. Movilli E; Cancarini GC; Vizzardi V; Camerini C; Brunori G; Cassamali S; Maiorca R J Nephrol; 2003; 16(4):546-51. PubMed ID: 14696757 [TBL] [Abstract][Full Text] [Related]
30. Erythropoietin requirements increase following hospitalization in end-stage renal disease patients. Yaqub MS; Leiser J; Molitoris BA Am J Nephrol; 2001; 21(5):390-6. PubMed ID: 11684801 [TBL] [Abstract][Full Text] [Related]
31. Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia. Rao DS; Shih MS; Mohini R N Engl J Med; 1993 Jan; 328(3):171-5. PubMed ID: 8417383 [TBL] [Abstract][Full Text] [Related]
32. Clinical effects of recombinant human erythropoietin in hemodialysis patients. Results of the "Abruzzo" Multicenter Trial. Di Paolo B; Di Liberato L; Summa R; Catucci G; Del Rosso G; Muscianese P; Albertazzi A ASAIO Trans; 1991; 37(3):M380-1. PubMed ID: 1751197 [TBL] [Abstract][Full Text] [Related]
33. The rate of increase in hematocrit, humoral vasoactive substances and blood pressure changes in hemodialysis patients treated with recombinant human erythropoietin or blood transfusion. Ono K; Hisasue Y Clin Nephrol; 1992 Jan; 37(1):23-7. PubMed ID: 1531789 [TBL] [Abstract][Full Text] [Related]
34. Erythropoietin with oral iron in peritoneal and hemodialysis patients. A comparison in an inner city population. Raja R; Bloom E; Goldstein M; Johnson R ASAIO J; 1993; 39(3):M578-80. PubMed ID: 8268603 [TBL] [Abstract][Full Text] [Related]
35. Association of quarterly average achieved hematocrit with mortality in dialysis patients: a time-dependent comorbidity-adjusted model. Messana JM; Chuang CC; Turenne M; Wheeler J; Turner J; Sleeman K; Tedeschi P; Hirth R Am J Kidney Dis; 2009 Mar; 53(3):503-12. PubMed ID: 19185402 [TBL] [Abstract][Full Text] [Related]
36. Adequacy of dialysis and differences in hematocrit among dialysis facilities. Ifudu O; Uribarri J; Rajwani I; Vlacich V; Reydel K; Delosreyes G; Friedman EA Am J Kidney Dis; 2000 Dec; 36(6):1166-74. PubMed ID: 11096041 [TBL] [Abstract][Full Text] [Related]
37. Secular trends in recombinant erythropoietin therapy among the U.S. hemodialysis population: 1990-1996. Cotter DJ; Thamer M; Kimmel PL; Sadler JH Kidney Int; 1998 Dec; 54(6):2129-39. PubMed ID: 9853279 [TBL] [Abstract][Full Text] [Related]
38. [Effect of recombinant human erythropoietin--rHu-EPO on the metabolism of children treated by long-term hemodialysis]. Pietrzyk JA; Smolnik T; Szymowska M; Dyras P; Lenik J Przegl Lek; 1992; 49(1-2):55-60. PubMed ID: 1455008 [TBL] [Abstract][Full Text] [Related]
39. Nonalcoholic fatty liver disease (NAFLD)--is it a new marker of hyporesponsiveness to recombinant human erythropoietin in patients that are on chronic hemodialysis? Orlic L; Mikolasevic I; Lukenda V; Racki S; Stimac D; Milic S Med Hypotheses; 2014 Dec; 83(6):798-801. PubMed ID: 25456789 [TBL] [Abstract][Full Text] [Related]
40. [The correction of anemia with a high requirement for transfusion in patients on maintenance hemodialysis by conventional and reduced doses of recombinant human erythropoietin]. Sivak L; Scuteri RM; Cavalli NH; Gotlieb D; López Blanco OA Medicina (B Aires); 1992; 52(6):516-22. PubMed ID: 1340900 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]